Impact of COVID-19 Pandemic on Respiratory Syncytial Virus (RSV) Prophylaxis Program: A Tertiary-Care Center Experience
Authors:
- Hamza M. KelabiHKHamza M. Kelabi
- Abdullah S. Alshamrani IiiAIAbdullah S. Alshamrani Iii
Open Access
- 27 July 2023
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 15 (7) , e42563
Abstract
Objectives: The purpose of this investigation was to evaluate the effects of the COVID-19 pandemic on the respiratory syncytial virus (RSV) prevention program at our institution across three time frames: 2019-2020, 2020-2021, and 2021-2022. Methods: We carried out a descriptive, single-site observational study spanning four years, from June 2019 to June 2022. Our study included patients in our institution's RSV program who met our enrollment criteria. We collected information about the number of children receiving immunoprophylaxis, immunoprophylaxis doses, and RSV risk factors. Results: The number of patients receiving immunoprophylaxis dropped across the three periods, from 315 patients in the first period (2019-2020) to 176 in the second period (2020-2021), and further decreased to 128 in the third period (2021-2022). Following the COVID-19 pandemic, there was a 50% reduction in the number of patients receiving immunoprophylaxis. The proportion of RSV-infected patients remained relatively similar in the first and second periods (2.86% and 2.27%, respectively) but increased in the third period (5.47%). In the first period, most patients (60.32%) received seven doses, 11.75% got four to six doses, and 27.95% received three doses or fewer. The second period saw 59.66% of patients receiving four to six doses and 40.34% receiving three doses or fewer. In the third period, a mere 9.38% received four to five doses, while 90.63% got three doses or fewer. Conclusions: While preventative measures associated with COVID-19 may have helped reduce the number of RSV cases, the pandemic seems to have caused a significant decrease in the number of children receiving immunoprophylaxis and the doses of immunoprophylaxis. More extensive, multicenter research is needed to understand the impact of the COVID-19 pandemic on RSV immunoprophylaxis, its activity, and seasonal patterns fully.Keywords
This publication has 40 references indexed in Scilit:
- Clinical manifestations and outcomes of respiratory syncytial virus infection in adult hospitalized patientsJournal of Clinical Virology, 2019
- Bronchiolitis in children: The Saudi initiative of bronchiolitis diagnosis, management, and prevention (SIBRO)Annals of Thoracic Medicine, 2018
- Interference Between Respiratory Syncytial Virus and Human Rhinovirus Infection in InfancyThe Journal of Infectious Diseases, 2017
- Bronchopulmonary Dysplasia: Chronic Lung Disease of Infancy and Long-Term Pulmonary OutcomesJournal of Clinical Medicine, 2017
- Respiratory Syncytial Virus Infection and BronchiolitisPediatrics in Review, 2014
- Viral etiology of respiratory infections in children in southwestern Saudi Arabia using multiplex reverse-transcriptase polymerase chain reactionSaudi Medical Journal, 2014
- Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab ProphylaxisThe Open Microbiology Journal, 2014
- Risk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract InfectionThe Open Microbiology Journal, 2011
- Respiratory Syncytial Virus in Patients with Congenital Heart Disease: A Contemporary Look at Epidemiology and Success of Preoperative ScreeningPediatric Cardiology, 2000
- INTERFERENCE BETWEEN OUTBREAKS OF RESPIRATORY SYNCYTIAL VIRUS AND INFLUENZA VIRUS INFECTIONThe Lancet, 1982